Pituitary-independent effect of octreotide on IGF1 generation

European Journal of Endocrinology

Volumn 160, Issue 4, 2009, Pages 543-548

  Pokrajac, Ana ^b   Frystyk, Jan ^a   Flyvbjerg, Allan ^a   Trainer, Peter J ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; HUMAN GROWTH HORMONE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG INHIBITION; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; PRIORITY JOURNAL; BIOSYNTHESIS; BLOOD; BODY MASS; GENETICS; HYPOPHYSIS; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY GLAND; YOUNG ADULT;

EID: 64549086809     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0822     Document Type: Article

References (49)

1. Reisine T & Bell GI. Molecular biology of somatostatin receptors. Endocrine Reviews 1995 16 427-442.
2. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, O'Carroll AM, Patel YC, Schonbrunn A & Taylor JE. Classification and nomenclature of somatostatin receptors. Trends in Pharmacological Sciences 1995 16 86-88.
3. Plewe G, Beyer J, Krause U, Neufeld M & Del PE. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet 1984 2 782-784.
4. Greenman Y & Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. Journal of Clinical Endocrinology and Metabolism 1994 79 724-729.
5. Greenman Y & Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 1994 78 398-403.
6. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT & Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1995 80 1386-1392.
7. Panetta R & Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sciences 1995 56 333-342.
8. Shimon I. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine 2003 20 265-269.
9. Ikuyama S, Nawata H, Kato K, Ibayashi H & Nakagaki H. Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. Journal of Clinical Endocrinology and Metabolism 1986 62 729-733.
10. Reubi JC & Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. Journal of Clinical Endocrinology and Metabolism 1989 68 844-850.
11. Takei M, Suzuki M, Kajiya H, Ishii Y, Tahara S, Miyakoshi T, Egashira N, Takekoshi S, Sanno N, Teramoto A & Osamura RY. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide. Endocrine Pathology 2007 18 208-216.
12. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B & LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. PNAS 1999 96 7324-7329.
13. Guler HP, Zapf J, Schmid C & Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinologica 1989 121 753-758.
14. Hwa V, Oh Y & Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocrine Reviews 1999 20 761-787.
15. Firth SM & Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews 2002 23 824-854.
16. Bates AS, Evans AJ, Jones P & Clayton RN. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clinical Endocrinology 1995 42 417-423.
17. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM & Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 1613-1617.
18. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K & Skakkebaek NE. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. Journal of Clinical Endocrinology and Metabolism 1994 78 744-752.
19. Burman P, Johansson AG, Siegbahn A, Vessby B & Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. Journal of Clinical Endocrinology and Metabolism 1997 82 550-555.
20. Parkinson C, Burman P, Messig M & Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2007 92 190-195.
21. Eden EB, Burman P & Karlsson FA. Men with acromegaly need higher doses of octreotide than women. Clinical Endocrinology 2002 56 73-77.
22. Svensson J, Johannsson G & Bengtsson BA. Insulin-like growth factor-I in growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test. Clinical Endocrinology 1997 46 579-586.
23. Colao A, Amato G, Pedroncelli AM, Baldelli R, Grottoli S, Gasco V, Petretta M, Carella C, Pagani G, Tambura G & Lombardi G. Gender- and age-related differences in the endocrine parameters of acromegaly. Journal of Clinical Investigation 2002 25 532-538.
24. Gleeson HK, Lissett CA & Shalet SM. Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. Journal of Clinical Endocrinology and Metabolism 2005 90 1061-1067.
25. Leung KC, Doyle N, Ballesteros M, Waters MJ & Ho KK. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. Journal of Clinical Endocrinology and Metabolism 2000 85 4712-4720.
26. Quabbe HJ & Plockinger U. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. Journal of Clinical Endocrinology and Metabolism 1989 68 873-881.
27. Tauber JP, Babin T, Tauber MT, Vigoni F, Bonafe A, Ducasse M, Harris AG & Bayard F. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 1989 68 917-924.
28. Pokrajac A, Claridge AG, Shakoor SK & Trainer PJ. The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. European Journal of Endocrinology 2006 154 267-274.
29. Flyvbjerg A, Jorgensen KD, Marshall SM & Orskov H. Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and organ growth in hypophysectomized rats. American Journal of Physiology 1991 260 E568-E574.
30. Zapf J, Gosteli-Peter M, Weckbecker G, Hunziker EB & Reinecke M. The somatostatin analog octreotide inhibits GH-stimulated, but not IGF-I-stimulated, bone growth in hypophysectomized rats. Endocrinology 2002 143 2944-2952.
31. Serri O, Brazeau P, Kachra Z & Posner B. Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action. Endocrinology 1992 130 1816-1821.
32. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism 1998 83 379-381.
33. Brabant G, von zur MA, Wuster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattsson A, Wilde J, Schemer R & Kann P. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Hormone Research 2003 60 53-60.
34. Frystyk J, Skjaerbaek C, Dinesen B & Orskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Letters 1994 348 185-191.
35. Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW & Flyvbjerg A. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. Journal of Clinical Endocrinology and Metabolism 2003 88 132-135.
36. Laursen T, Moller J, Fisker S, Jorgensen JO & Christiansen JS. Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients. Growth Hormone and IGF Research 1999 9 451-457.
37. Zapf J, Hauri C, Futo E, Hussain M, Rutishauser J, Maack CA & Froesch ER. Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats. Journal of Clinical Investigation 1995 95 179-186.
38. Firth SM, McDougall F, McLachlan AJ & Baxter RC. Impaired blockade of insulin-like growth factor I (IGF-I)-induced hypoglycemia by IGF binding protein-3 analog with reduced ternary complex-forming ability. Endocrinology 2002 143 1669-1676.
39. Frystyk J, Ivarsen P, Stoving RK, Dall R, Bek T, Hagen C & Orskov H. Determination of free insulin-like growth factor-I in human serum: comparison of ultrafiltration and direct immunoradiometric assay. Growth Hormone and IGF Research 2001 11 117-127.
40. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y & Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. Journal of Clinical Investigation 2004 114 349-356.
41. Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, Leong GM, Ross RJ & Ho KK. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. PNAS 2003 100 1016-1021.
42. Lee PD, Giudice LC, Conover CA & Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proceedings of the Society for Experimental Biology and Medicine 1997 216 319-357.
43. Pao CI, Farmer PK, Begovic S, Villafuerte BC,Wu GJ, Robertson DG & Phillips LS. Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein 1 gene transcription by hormones and provision of amino acids in rat hepatocytes. Molecular Endocrinology 1993 7 1561-1568.
44. Wolthers T, Grofte T, Flyvbjerg A, Frystyk J, Vilstrup H, Orskov H & Foegh M. Dose-dependent stimulation of insulin-like growth factor-binding protein-1 by lanreotide, a somatostatin analog. Journal of Clinical Endocrinology and Metabolism 1994 78 141-144.
45. Rajaram S, Baylink DJ & Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrine Reviews 1997 18 801-831.
46. Strowski MZ & Blake AD. Function and expression of somatostatin receptors of the endocrine pancreas. Molecular and Cellular Endocrinology 2008 286 169-179.
47. Hofland LJ, van der HJ, Feelders R, van der Lely AJ, de HW & Lamberts SW. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. Journal of Clinical Investigation 2005 28 36-42.
48. Hofland LJ, van der HJ, Feelders R, van AkenMO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A & Lamberts SW. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. European Journal of Endocrinology 2005 152 645-654.
49. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW & van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. Journal of Clinical Endocrinology and Metabolism 2007 92 4598-4601.